WGNO26d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS ...
JD Supra7d
Teva Announces New Biosimilar Deals
Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...
Business Insider26d
Samsung Bioepis, Teva Enter License, Development, Commercialization Agreement For EPYSQLI
(RTTNews) - Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis biosimilar to ...